These findings are consistent with other breast cancer studies showing that PIK3CA lesions are the most frequent mutation in ER-positive cancer24, while mutations in ESR1 and KRAS may emerge in advanced disease as a response to drug intervention15,25,26. This evidence concerns the gene ESR1 and breast carcinoma.